Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

Markets & Finance

Thomas Weisel Raises Biosite Outlook

Thomas Weisel raised estimates on Biosite (BSTE).

Analyst David Lewis says the 37 cents first-quarter earnings per share beat his 32 cents estimate, and the $39.9 million revenue estimate beat his $35.4 million estimate. He says sales of the Triage BNP test, which helps to diagnose congestive heart failure, continues to drive Biosite's business.

Lewis says the first quarter was excellent, and he thinks end-user demand for BNP products remains strong. He notes, based on expected strength, Biosite raised the 40%-50% 2003 revenue growth guidance to 60%-80%, and upped the 60%-70% earnings per share growth to 80%-100%. He doesn't expect Bayer to enter the market until the second half of 2003, pointing to more Triage BNP business for Biosite.

Lewis raised his $1.43 2003 earnings per share estimate to $1.58, and upped the $1.65 2004 estimate to $1.76. He is keeping his peer perform rating.

blog comments powered by Disqus